Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Uber Technologies Inc (UBER) Price & Performance

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.

Uber (UBER) trades at $71.5, showing minimal daily change. The stock exhibits a bullish technical signal overall, with strong fundamentals including a 19.3% net income margin and robust revenue growth to $52.0B in 2025. Recent news highlights expansion of the Uber Eats partnership with Costco to 47 states, enhancing delivery reach. Cash flow from operations remains strong at $10.1B, though 2026 projections indicate a net cash outflow. Analyst sentiment is overwhelmingly positive with an 82.5% buy rating and a consensus price target of $104.72.

The outlook for Uber is favorable, driven by strategic expansions and solid financial performance. Investment opportunities include market share gains in mobility and delivery, supported by high institutional confidence. Key risks involve competitive pressures in autonomous vehicles, execution of growth initiatives, and potential macroeconomic headwinds affecting consumer spending. The stock's current valuation metrics, such as a P/E of 15.6, suggest room for appreciation relative to analyst targets.